Gujarat Themis Biosyn Limited — PPTs, 25-05-2026: Investor Presentation

**Gujarat Themis Biosyn Q4 & FY26 Update:** The company closed FY26 strong, with Q4 revenue up 17% YoY to Rs. 44.2 Cr and EBITDA up 20.7% to Rs. 19.4 Cr. For the full year, revenue grew nearly 10% to Rs. 165.8 Cr and EBITDA rose 9.7% to Rs. 75.5 Cr. Profit After Tax declined slightly due to higher depreciation and interest costs from significant growth-focused capital expenditure.

Strategic moves include acquiring 13 brands from Sanofi (EUR 158 Mn, asset-light, global reach in TB/anti-infectives) and Japan's MicroBiopharm (JPY 21.5 Bn, ~Rs. 1,300 Cr, expanding CDMO capabilities and product portfolio). R&D and API units are operational, and a new fermentation block is complete. A hybrid wind-solar plant is being set up to cut costs and improve environmental sustainability. Management sees robust demand and focuses on new product development, forward integration, and geographical expansion. Earnings Per Share for Q4 was Rs. 1.00 and for FY26 was Rs. 4.28.